Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved
By Katherine HamiltonAscendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk.The Danish company said Monday it can develop, manufacture and commercialize TransCon technology-based products in metabolic and cardiov…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.